Cytokinetics Wins Health Canada Approval for MYQORZO to Treat Obstructive HCM

Bitget2026/10/19 11:36

By:Bitget

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Health Canada approved Cytokinetics' MYQORZO (aficamten) for adults with symptomatic obstructive hypertrophic cardiomyopathy classified as NYHA class II-III.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190730PRIMZONEFULLFEED9848098) on October 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Cytokinetics Wins Health Canada Approval for MYQORZO to Treat Obstructive HCM

You may also like

Crypto prices